Document Type : Original Paper


1 Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran

2 National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

3 Department of Biology, School of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran

4 Department of Cellular and Molecular Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran.


Breast cancer is the most prevalent malignancy and the second in mortality rate cancers among all cancers in women globally. In Iran it adds up to 16 percent of all cancers and is the most prevalent cancer in Iranian women. PALB2, identified as a partner and localizer of BRCA2 and proposed to have some roles in DNA damage response, has recently been identified as a breast cancer marker gene. Considering the importance of the breast cancer in Iranian women population, in the present study we aim to make clear whether the expression level of the PALB2 could be accounted as a biomarker in timely diagnosis and also a deterministic factor in prognosis of breast cancer. Accordingly, the real-time PCR has been usedto evaluate PALB2 expression in blood samples acquired from 40 cancer patients and 10 normal women. Having been investigated in this Iranian women population with breast cancer, the PALB2 gene expression has shown a borderline significant increase, as compared to normal cases (P value = 0.0499). Furthermore, in this study, the correlation between PALB2 gene expression and several risk factors in breast cancer including age, menstrual state, family history of breast cancer as well as family history of other cancers has also been studied.


  1. Christgen M., Steinemann D., Kühnle E., Länger F., Gluz O., Harbeck N., and Kreipe H. Lobular breast cancer: Clinical, molecular and morphological characteristics. Res. Pract. 212(7): 583-597 (2016).
  2. Thivyah Prabha A.G., and Sekar D. Deciphering the molecular signaling pathways in breast cancer pathogenesis and their role in diagnostic and treatment modalities. Gene Rep. 7: 1-17 (2017).
  3. Gómez-Flores-Ramos L., Álvarez-Gómez R. M., Villarreal-Garza C., Wegman-Ostrosky T., and Mohar A. Breast cancer genetics in young women: What do we know? Mutat. Res. Rev. Mutat. Res. 774: 33-45 (2017).
  4. Tabarestani S., and Noori-Daloii M.R. Molecular genetics, diagnosis and treatment of breast cancer: Review article. J. Sabzevar Univ. Med. Sci. 17(2): 74-87 (2010).
  5. Antoniou A.C., and Easton D.F. Models of genetic susceptibility to breast cancer. Oncogene. 25(43): 5898-905 (2006).
  6. Kleibl Z., and Kristensen V.N. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management. Breast. 28: 136-44 (2016).
  7. Ban K.A., and Godellas C.V. Epidemiology of breast cancer. Surg. Oncol. Clin. N. Am. 23(3): 409-22 (2014).
  8. Li F., Zhou J., Xu M., and Yuan, G. Investigation on the formation, conversion and bioactivity of a G-quadruplex structure in the PALB2 gene. Int. J. Biol. Macromol. 83: 242-248 (2016).


  1. Li Y. T., Jiang W. H., Wang,X. W., Zhang M. S., Zhang C. G., Yi L. N., and Ou, J. H. PALB2 mutations in breast cancer patients from a multi-ethnic region in northwest China. Eur. J. Med. Res. 20(85): 1-5 (2015).
  2. Wesola, M., and Jelen, M. The risk of breast cancer due to PALB2 gene mutations. Adv. Clin. Exp. Med. 26(2): 339-342 (2017).
  3. Lee J.E.A., Li N., Rowley S.M., Cheasley D., Zethoven M., McInerny S., Gorringe K.L., James P.A., and Campbell I.G. Molecular analysis of PALB2‐associated breast cancers. J. Pathol. 245(1): 53-60 (2018).
  4. Nepomuceno T., De Gregoriis G., de Oliveira F.M.B., Suarez-Kurtz G., Monteiro A., and Carvalho, M. The role of PALB2 in the DNA damage response and cancer predisposition. Int. J. Mol. Sci. 18(9): 1-8 (2017).


  1. Li J., Li M., Chen P., and Ba Q. High expression of PALB2 predicts poor prognosis in patients with advanced breast cancer. FEBS Open Bio. 8(1): 56-63 (2018).
  2. Park J.Y., Zhang F., and Andreassen P.R. PALB2: the hub of a network of tumor suppressors involved in DNA damage responses. Biochim. Biophys. Acta. 1846(1): 263-75 (2014).